Stephen Hoge
CIK 1760669 · President · last filed 2026-10-16
Stephen Hoge is a President who has filed 216 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for MRNA, was dated Oct 16, 2026. Across all open-market trades the lifetime net is −$341.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $381.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MRNA | President | 1,679,826 | $226.89 | $381.14M | -$341.27M | 171 | 2026-10-16 |
| Axcella Health Inc. (AXLA) Delisted | Director | — | $0.40 | — | $0 | 3 | 2021-05-24 |
Recent Filings
216 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-16 | MRNA | Mixed | +74,536 | -$15.15M | EDGAR |
| 2026-10-15 | MRNA | Notice (144) | −39,145 | -$8.64M | EDGAR |
| 2026-10-14 | MRNA | Notice (144) | −39,224 | -$8.37M | EDGAR |
| 2026-09-16 | MRNA | Mixed | +72,330 | -$9.82M | EDGAR |
| 2026-09-15 | MRNA | Notice (144) | −40,281 | -$5.88M | EDGAR |
| 2026-09-14 | MRNA | Notice (144) | −40,294 | -$5.81M | EDGAR |
| 2026-09-03 | MRNA | Mixed | +4,794 | -$630.0K | EDGAR |
| 2026-08-31 | MRNA | Mixed | +1,057 | -$146.3K | EDGAR |
| 2026-07-16 | MRNA | Mixed | — | -$2.58M | EDGAR |
| 2026-07-15 | MRNA | Notice (144) | −53,336 | -$3.61M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.